ENSC Valuation

Ensysce Biosciences Inc

Add to Watchlist

Advanced Chart

2.460

+0.04(1.653%)1D

Overview
Forecast
Valuation
Earnings

ENSC Relative Valuation

ENSC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ENSC is overvalued; if below, it's undervalued.

Historical Valuation

Ensysce Biosciences Inc (ENSC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -2.26. The fair price of Ensysce Biosciences Inc (ENSC) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.37

Fair

-0.87

Trailing

Forward

-0.36

EV/EBITDA

Ensysce Biosciences Inc. (ENSC) has a current EV/EBITDA of -0.36. The 5-year average EV/EBITDA is -0.27. The thresholds are as follows: Strongly Undervalued below -1.39, Undervalued between -1.39 and -0.83, Fairly Valued between 0.28 and -0.83, Overvalued between 0.28 and 0.84, and Strongly Overvalued above 0.84. The current Forward EV/EBITDA of -0.36 falls within the Historic Trend Line -Fairly Valued range.

-0.36

EV/EBIT

Ensysce Biosciences Inc. (ENSC) has a current EV/EBIT of -0.36. The 5-year average EV/EBIT is -90.57. The thresholds are as follows: Strongly Undervalued below -659.94, Undervalued between -659.94 and -375.25, Fairly Valued between 194.12 and -375.25, Overvalued between 194.12 and 478.80, and Strongly Overvalued above 478.80. The current Forward EV/EBIT of -0.36 falls within the Historic Trend Line -Fairly Valued range.

2.55

Ensysce Biosciences Inc. (ENSC) has a current PS of 2.55. The 5-year average PS is 661.62. The thresholds are as follows: Strongly Undervalued below -3478.68, Undervalued between -3478.68 and -1408.53, Fairly Valued between 2731.77 and -1408.53, Overvalued between 2731.77 and 4801.93, and Strongly Overvalued above 4801.93. The current Forward PS of 2.55 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Ensysce Biosciences Inc. (ENSC) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.11. The thresholds are as follows: Strongly Undervalued below -0.51, Undervalued between -0.51 and -0.31, Fairly Valued between 0.09 and -0.31, Overvalued between 0.09 and 0.29, and Strongly Overvalued above 0.29. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Ensysce Biosciences Inc. (ENSC) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.

Ensysce Biosciences Inc (ENSC) has a current Price-to-Book (P/B) ratio of 1.71. Compared to its 3-year average P/B ratio of 1.93 , the current P/B ratio is approximately -11.56% higher. Relative to its 5-year average P/B ratio of -10777.08, the current P/B ratio is about -100.02% higher. Ensysce Biosciences Inc (ENSC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -258.36%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -167.85% , the current FCF yield is about -100.00% lower.

1.71

P/B

Median3y

1.93

Median5y

-10777.08

-85.93

FCF Yield

Median3y

-258.36

Median5y

-167.85

Competitors Valuation Multiple

The average P/S ratio for ENSC's competitors is 0.00, providing a benchmark for relative valuation. Ensysce Biosciences Inc Corp (ENSC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 654.38%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ENSC.O

Ensysce Biosciences Inc

Calidi Biotherapeutics Inc

Entero Therapeutics Inc

Avalon Globocare Corp

Loss

6.87%

9.17M

Performance Decomposition

Market capitalization of ENSC decreased by 71.99% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 181.80K to 1.37M.

The secondary factor is the Margin Expansion, contributed -88.32%to the performance.

Overall, the performance of ENSC in the past 1 year is driven by Revenue Growth. Which is more sustainable.

654.38%

181.80K → 1.37M

Revenue Growth

-88.32%

-1.08K → -126.40

Margin Expansion

-638.05%

0.09 → -0.49

P/E Change

-71.99%